Neoadjuvant treatment for esophageal squamous cell carcinoma

Table 1 Neoadjuvant radiotherapy treatment and outcomes for esophageal squamous cell carcinoma

Ref.	Year of publication	Histology	Treatment	n	Median survival (mo)	5-yr overall survival (%)	P
Launois et al[17]	1981	SCC	RT 40 Gy → Surgery	77	10	10	NS
			Surgery	57	12	12
Gignoux et al[18]	1987	SCC	RT 33 Gy → Surgery	106	11	11	NS
			Surgery	102	11	10
Arnott et al[19]	1992	AC/SCC	RT 20 Gy → Surgery	90	8	9	NS
		(36%)	Surgery	86	8	17
Nygaard et al[20]	1992	SCC	RT 35 Gy → Surgery	48		211	0.080
			Surgery	41		9
Wang et al[21]	1989	SCC	RT 40 Gy → Surgery	104		35	NS
			Surgery	102		30
Cao et al[22]	2009	SCC	RT 40 Gy → Surgery	118		701	0.0051
			Surgery	118		53
Chu et al[23]	1994	SCC	RT 24-53 Gy → Surgery	40	11	10	NS
			Surgery → RT 45-53 Gy	42	11	10

¹3-yr overall survival. AC: Adenocarcinoma; NS: Not significant; RT: Radiation therapy; SCC: Squamous cell carcinoma.

Table 2 Neoadjuvant chemotherapy treatment and outcomes for esophageal squamous cell carcinoma

Ref.	Year of publication	Histology	Treatment	n	Median survival (mo)	5-yr overall survival (%)	P
Schlag[26]	1992	SCC	FU, CDDP → Surgery	22	10		NS
			Surgery	24	10
Nygaard et al[20]	1992	SCC	CDDP, BL → Surgery	44	7	31
			Surgery	41	7	9
Maipang et al[27]	1994	SCC	CDDP, BL, VI → Surgery	24	17	311	NS
			Surgery	22	17	36
Law et al[28]	1997	SCC	FU, CDDP → Surgery	66	17	401	NS
			Surgery	69	13	13
Ancona et al[29]	2001	SCC	FU, CDDP → Surgery	47	25	34	NS
			Surgery	47	24	22
Kelsen et al[32]	2007	AC/SCC	FU, CDDP → Surgery	213	15	19	NS
(RTOG 8911)		(47%)	Surgery	227	16	20
Allum et al[31]	2009	AC/SCC	FU, CDDP → Surgery	400	17	23	< 0.01
(OEO2)		(31%)	Surgery	402	13	17
Ando et al[7]	2012	SCC	FU, CDDP → Surgery	164		55	0.01
(JCOG9907)			Surgery → FU, CDDP	166		43

¹3-yr overall survival. AC: Adenocarcinoma; BL: Bleomycin; CDDP: Cisplatin; FU: Fluorouracil; NS: Not significant; SCC: Squamous cell carcinoma; VI: Vinblastine; JCOG: Japan Clinical Oncology Group study.

Table 3 Neoadjuvant chemoradiotherapy treatment and outcomes for esophageal squamous cell carcinoma

Ref.	Year of publication	Histology	Treatment	n	Median survival (mo)	5-yr overall survival (%)	P
Nygaard et al[20]	1992	SCC	CDDP, BL + 35 Gy → Surgery	47	8	171
			Surgery alone	41	7	9
Le Prise et al[47]	1994	SCC	CDDP, FU + 20 Gy → Surgery	41		472	NS
			Surgery alone	45		47
Apinop et al[48]	2004	SCC	CDDP, FU + 40 Gy → Surgery	35	10	24	NS
			Surgery alone	34	7	10
Bosset et al[15]	1997	SCC	CDDP + 37 Gy → Surgery	143	19	7
			Surgery	139	19	9
Urba et al[49]	2001	AC/SCC	CDDP, FU, VI + 45 Gy → Surgery	50	17	16	NS
		(25%)	Surgery alone	50	18	30
Heise et al[50]	2001	SCC	FU, LV, ET, CDDP + RT→ Surgery	33	20	26
			Surgery alone	170	14	17
Lee et al[51]	2004	SCC	CDDP, FU + 45 Gy → Surgery	51	28	553
			Surgery alone	50	27	57
Burmeister et al[52]	2005	AC/SCC	CDDP, FU + 35 Gy → Surgery	128	22	17	NS
		(35%)	Surgery alone	128	19	13
Natsugoe et al[53]	2006	SCC	CDDP, FU + 40 Gy → Surgery	22		57	NS
			Surgery alone	23		41
Tepper et al[54]	2008	AC/SCC	CDDP, FU + 50 Gy → Surgery	30	54	39	0.002
(CALGB9781)		(75%)	Surgery alone	26	23	16
Cao et al[22]	2009	SCC	CDDP, FU, MMC + 40 Gy → Surgery	118		731	< 0.01
			Surgery alone	118		53
Lv et al[55]	2010	SCC	CDDP, PTX + 40 Gy → Surgery	80	53	44	0.040
			Surgery alone	80	36	34
Van Hagen et al[56]	2012	AC/SCC	CA, PTX + 41 Gy → Surgery	178	49	47	0.003
(CROSS)		(23%)	Surgery	188	24	34

¹3-yr overall survival;

²1-yr overall survival;

³2-yr overall survival. AC: Adenocarcinoma; BL: Bleomycin; CA: Carboplatin; CDDP: Cisplatin; DO: Doxorubicin; FU: Fluorouracil; ET: Etoposide; NS: Not significant; PTX: Paclitaxel; SCC: Squamous cell carcinoma; VI: Vinblastine; CALGB: Cancer and Leukemia Group B.